Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.


Experts meet in Geneva to review Ebola vaccines: WHO

07 January 2015, 19:36

Geneva - Experts will gather in Geneva this week to review progress on possible vaccines against the deadly Ebola virus, the World Health Organization said Wednesday.

The international health community is desperately trying to find a vaccine to fight the virus, which continues to rage in west Africa where it has killed more than 8,200 people.

Thursday's high-level meeting will be a follow-up to a conference held in October and will provide an update on the safety and efficacy of the possible vaccines undergoing clinical trials.

Participants, including health officials, vaccine manufacturers and government representatives from the hardest-hit countries will also review available financing to bring promising candidate vaccines to the market.

They will also look at ways to ensure the broadest possible access once a safe and efficient vaccine is found.

And they will discuss preparations for Phase III efficacy trials in Guinea, Sierra Leone and Libera, which are at the epicentre of the outbreak.

Also read: 'Containment of Ebola a major achievement in 2014'

There is no licensed treatment or vaccine for Ebola, and the WHO has endorsed rushing potential ones through trials in a bid to stem the epidemic.

Human trials have begun on three possible vaccines, with Johnson & Johnson announcing Tuesday that its proposed vaccine was being tested on volunteers in Britain.

Another experimental vaccine, ChAd3, made by Britain's GlaxoSmithKline, is undergoing clinical tests in Switzerland, Mali, Britain and the United States.

A third promising candidate, the VSV-ZEBOV, manufactured by the Public Health Agency of Canada and licenced by US firm NewLink Genetics, is also being tested in the United States, Canada, Germany and Gabon.

Tests of VSV-ZEBOV on volunteers in Switzerland were meanwhile briefly suspended late last year over concerns over unexpected side-effects, but resumed this week after the doses being injected were reduced.


Tags geneva ebola

Read News24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Read more from our Users

Nigeria @ 56: Words to my green f...

A leader’s job is not to dictate, but rather to be respected, admired and be a trustee, of the land we love, with so much potential, a land which should be freer than free. Its still a long way to fufilling our destiny! Read more...

Submitted by
Isaac Asabor263
Recession: An opportunity for Nig...

The recession should be seen as an opportunity for the country’s promotion as long as we all collectively conduct ourselves in a patriotic manner, writes Isaac Asabor.  Read more...

Submitted by
Black and White

We want to imitate the whites in everything because we are ignorant of our inherent originality and content. We spend all our Naira to acquire his inventions because we so oblivious of our natural endowments that we allow him have it for free. Read more...

Submitted by
Nate Nat
Adamawa State University Mubi: A ...

ADSU integrity forum has accused the Sunday Joshua Wugira, a lawyer, of adopting unorthodox tactics by abusing his privilege by attacking the integrity of ADSU Vice Chancellor Dr. Moses Zira Zaruwa, writes a News24 reader. Read more...

Submitted by
Abdulsalam Jubril
My Country Nigeria (Part One)

Poetry by Abdulsalam Jubril.

Submitted by
Abdulsalam Jubril
Recession, dearth in leadership a...

Every leader has the opportunity to become great and making himself immortal in the lives and hearts of people for generations to come. Will Mr. President seize this opportunity?, questions Abdulsalam Jubril. Read more...